Literature DB >> 12007561

Homologous recombinational repair vis-à-vis chlorambucil resistance in chronic lymphocytic leukemia.

Vanessa E Bello1, Raquel S Aloyz, Garyfallia Christodoulopoulos, Lawrence C Panasci.   

Abstract

The objective of this study was to further define the role of homologous recombinational repair (HRR) in resistance to the nitrogen mustards in B-cell chronic lymphocytic leukemia (B-CLL). We have demonstrated previously that increased chlorambucil (CLB)-induced HsRad51 nuclear foci formation correlated with a CLB-resistant phenotype in B-CLL lymphocytes. In this report, we measured the protein levels of HsRad51 and Xrcc3 (an HsRad51 paralog) and correlated them with the in vitro CLB cytotoxicity (LD(50)) in lymphocytes from seventeen B-CLL patients. Both HsRad51 (r=0.75, P=0.0005) and Xrcc3 (r=0.52, P=0.03) protein levels correlated with the in vitro CLB LD(50). In addition, multiple linear regression analysis showed a significant correlation between Xrcc3 and Rad51 protein levels versus the CLB LD(50) (r=0.78, P=0.0014), suggesting that both proteins influence CLB cytotoxicity. Moreover, since HsRad51 expression varies in cell lines during the cell cycle, we determined proliferating cell nuclear antigen (PCNA) protein levels to assess possible differences in cell cycle progression. There was no correlation between PCNA protein levels and the CLB LD(50) (r=0.042, P=0.87) or with HsRad51/Xrcc3 protein levels. Our data suggest that HsRad51 and Xrcc3 protein expression may be predictive of the response in B-CLL patients to treatment with nitrogen mustards.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12007561     DOI: 10.1016/s0006-2952(02)00954-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  14 in total

Review 1.  The role of DNA repair in chronic lymphocytic leukemia pathogenesis and chemotherapy resistance.

Authors:  Deepa Sampath; William Plunkett
Journal:  Curr Oncol Rep       Date:  2007-09       Impact factor: 5.075

2.  The RAD51-stimulatory compound RS-1 can exploit the RAD51 overexpression that exists in cancer cells and tumors.

Authors:  Jennifer M Mason; Hillary L Logan; Brian Budke; Megan Wu; Michal Pawlowski; Ralph R Weichselbaum; Alan P Kozikowski; Douglas K Bishop; Philip P Connell
Journal:  Cancer Res       Date:  2014-04-21       Impact factor: 12.701

3.  An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity.

Authors:  Brian Budke; Jay H Kalin; Michal Pawlowski; Anna S Zelivianskaia; Megan Wu; Alan P Kozikowski; Philip P Connell
Journal:  J Med Chem       Date:  2012-12-26       Impact factor: 7.446

Review 4.  Crosstalk between translesion synthesis, Fanconi anemia network, and homologous recombination repair pathways in interstrand DNA crosslink repair and development of chemoresistance.

Authors:  Brittany Haynes; Nadia Saadat; Brian Myung; Malathy P V Shekhar
Journal:  Mutat Res Rev Mutat Res       Date:  2014-11-20       Impact factor: 5.657

Review 5.  Recent Developments Using Small Molecules to Target RAD51: How to Best Modulate RAD51 for Anticancer Therapy?

Authors:  Brian Budke; Wei Lv; Alan P Kozikowski; Philip P Connell
Journal:  ChemMedChem       Date:  2016-10-26       Impact factor: 3.466

6.  Optimization of Drug Candidates That Inhibit the D-Loop Activity of RAD51.

Authors:  Brian Budke; Werner Tueckmantel; Kelsey Miles; Alan P Kozikowski; Philip P Connell
Journal:  ChemMedChem       Date:  2019-04-17       Impact factor: 3.466

7.  Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro.

Authors:  Robert L Dilley; Weijie Poh; Douglas E Gladstone; James G Herman; Margaret M Showel; Judith E Karp; Michael A McDevitt; Keith W Pratz
Journal:  Leuk Res       Date:  2013-12-30       Impact factor: 3.156

8.  Development of Small Molecules that Specifically Inhibit the D-loop Activity of RAD51.

Authors:  Wei Lv; Brian Budke; Michal Pawlowski; Philip P Connell; Alan P Kozikowski
Journal:  J Med Chem       Date:  2016-04-21       Impact factor: 7.446

9.  A role for XRCC2 gene polymorphisms in breast cancer risk and survival.

Authors:  Wei-Yu Lin; Nicola J Camp; Lisa A Cannon-Albright; Kristina Allen-Brady; Sabapathy Balasubramanian; Malcolm W R Reed; John L Hopper; Carmel Apicella; Graham G Giles; Melissa C Southey; Roger L Milne; Jose I Arias-Pérez; Primitiva Menéndez-Rodríguez; Javier Benítez; Magdalena Grundmann; Natalia Dubrowinskaja; Tjoung-Won Park-Simon; Thilo Dörk; Montserrat Garcia-Closas; Jonine Figueroa; Mark Sherman; Jolanta Lissowska; Douglas F Easton; Alison M Dunning; Preetha Rajaraman; Alice J Sigurdson; Michele M Doody; Martha S Linet; Paul D Pharoah; Marjanka K Schmidt; Angela Cox
Journal:  J Med Genet       Date:  2011-05-31       Impact factor: 6.318

10.  RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells.

Authors:  Brian Budke; Hillary L Logan; Jay H Kalin; Anna S Zelivianskaia; William Cameron McGuire; Luke L Miller; Jeremy M Stark; Alan P Kozikowski; Douglas K Bishop; Philip P Connell
Journal:  Nucleic Acids Res       Date:  2012-05-09       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.